Background: The transformation of epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) into small cell cancer (SCLC) accounts for 3–14% the resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs). At present, there is no relevant research explore dynamic expression EGFR-mutant proteins and genomic evolution in transformed SCLC/neuroendocrine carcinoma (NEC).

Signalling through protein tyrosine kinases (PTKs) is critical in the regulation of important cellular processes and its deregulation is associated with pathophysiological disorders such as cancer. We investigated the function of the PTK spleen tyrosine kinase (Syk) in the regulation of growth factor signalling pathways in human mammary epithelial cells. Our results show that downregulation of ...

OBJECTIVE Somatic mutations in the epidermal growth factor receptor gene are associated with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors such as gefitinib and erlotinib in patients with non-small cell lung cancer. Although the safety profile of these drugs is favorable, a small proportion of patients with EGFR mutation-positive non-small cell lung cance...

Activating mutations in Epidermal growth factor receptor (EGFR) occur approximately 15% White, 40-50% of Asian and Black patients with lung adenocarcinoma. However, its prevalence the nearly 60 million U.S. Hispanics has not been well characterized. Herein we evaluate EGFR mutation frequency Hispanic adenocarcinoma at an academic institute serving a large multi-ethnic area.

Functional foods have emerged as a new approach to improve human health in term of nutraceutical to prevent people from illness rather than cure patients though medical treatment. In Asian society, particularly in Thailand, the utilizations of functional ingredients have been integrated in every parts of ordinary life. In this study, the tyrosine kinase activity of epidermal growth factor recep...

Quantitative epidermal growth factor (EGF)-binding experiments have shown that the EGF-receptor (EGFR) is displayed on the surface of intact cells in two forms, a minority of high-affinity and a majority of low-affinity EGFRs. On the basis of the three-dimensional structure of the extracellular ligand binding domain of the EGFR, it was proposed that the intramolecularly tethered and autoinhibit...

Functional foods have emerged as a new approach to improve human health in term of nutraceutical to prevent people from illness rather than cure patients though medical treatment. In Asian society, particularly in Thailand, the utilizations of functional ingredients have been integrated in every parts of ordinary life. In this study, the tyrosine kinase activity of epidermal growth factor recep...

Nearly 50 % of newly diagnosed colorectal cancer, affect people over 70 years of age. Inclusion of older patients in clinical trials has been extremely rare. As a result, there is debate on how to manage these patients because it is still unclear how to balance the therapeutic advantages and toxicities. For patients who do not have comorbid conditions, with performance status (P.S.) 0–1, treatm...

Background: Lazertinib is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to overcome EGFR T790M mutation. Currently, lazertinib approved for usage in the acquired mutation population based on promising clinical and safety profiles. In this study, we evaluated outcomes of mutated non-small cell lung cancer (NSCLC) patients real-world setting.